Vaccines for cytomegalovirus

Infectious Disorders - Drug Targets

Volumn 11, Issue 5, 2011, Pages 514-525

  Bernstein, D I ^a  

^a NONE   (United States)

Author keywords

Chimeric; Congenital infection; Cytomegalovirus; DNA vaccines; Replicons; Vectors

Indexed keywords

CANARYPOX VACCINE; CYTOMEGALOVIRUS VACCINE; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; LIVE VACCINE; PEPTIDE VACCINE; RECOMBINANT GLYCOPROTEIN B VACCINE; RECOMBINANT PROTEIN; TOLEDO STRAIN VACCINE; TOWNE STRAIN VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VENEZUELAN EQUINE ENCEPHALITIS VACCINE; VIRUS VACCINE;

ARTICLE; BONE MARROW TRANSPLANTATION; CANARYPOX VIRUS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM INFECTION; CHOLECYSTITIS; CLINICAL TRIAL; COLITIS; CONGENITAL INFECTION; COST BENEFIT ANALYSIS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; ESOPHAGITIS; FEMALE; GENOTYPE; GRAFT REJECTION; HEART GRAFT; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INNATE IMMUNITY; KIDNEY GRAFT; LIVER GRAFT; LUNG TRANSPLANTATION; MOUTH ULCER; MYCOSIS; NATURAL KILLER CELL; NONHUMAN; OPEN READING FRAME; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PERCEPTION DEAFNESS; PNEUMONIA; PREGNANCY; RETINITIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VENEZUELAN EQUINE ENCEPHALITIS; VIRUS ATTENUATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 80054089805     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/187152611797636695     Document Type: Article

References (157)

1. Whitley, R.J. Congenital cytomegalovirus infection: epidemiology and treatment. Adv. Exp. Med. Biol., 2004, 549, 155-160.
2. Adler, S.P.; Marshall, B. Cytomegalovirus infections. Pediatr. Rev., 2007, 28(3), 92-100.
3. High, K.P. Atherosclerosis and infection due to Chlamydia pneumoniae or cytomegalovirus: weighing the evidence. Clin. Infect. Dis., 1999, 28(4), 746-749.
4. Vasto, S.; Colonna-Romano, G.; Larbi, A.; Wikby, A.; Caruso, C.; Pawelec, G. Role of persistent CMV infection in configuring T cell immunity in the elderly. Immun. Ageing, 2007, 4, 2.
5. Newkirk, M.M.; van Venrooij, W.J.; Marshall, G.S. Autoimmune response to U1 small nuclear ribonucleoprotein (U1 snRNP) associated with cytomegalovirus infection. Arthritis Res., 2001, 3(4), 253-258.
6. Fowler, K.B.; Stagno, S.; Pass, R.F.; Britt, W.J.; Boll, T.J.; Alford, C.A. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med., 1992, 326(10), 663-667.
7. Williamson, W.D.; Demmler, G.J.; Percy, A.K.; Catlin, F.I. Progressive hearing loss in infants with asymptomatic congenital cytomegalovirus infection. Pediatrics, 1992, 90(6), 862-866.
8. Fowler, K.B.; McCollister, F.P.; Dahle, A.J.; Boppana, S.; Britt, W.J.; Pass, R.F. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J. Pediatr., 1997, 130(4), 624-630.
9. Lanari, M.; Lazzarotto, T.; Venturi, V.; Papa, I.; Gabrielli, L.; Guerra, B.; Landini, M.P.; Faldella, G. Neonatal cytomegalovirus blood load and risk of sequelae in symptomatic and asymptomatic congenitally infected newborns. Pediatrics, 2006, 117(1), e76-e83.
10. Boppana, S.B.; Fowler, K.B.; Pass, R.F.; Rivera, L.B.; Bradford, R.D.; Lakeman, F.D.; Britt, W.J. Congenital cytomegalovirus infection: association between virus burden in infancy and hearing loss. J. Pediatr., 2005, 146(6), 817-823.
11. Ross, S.A.; Novak, Z.; Fowler, K.B.; Arora, N.; Britt, W.J.; Boppana, S.B. Cytomegalovirus blood viral load and hearing loss in young children with congenital infection. Pediatr. Infect. Dis. J., 2009, 28(7), 588-592.
12. Grant, S.; Edmond, E.; Syme, J. A prospective study of cytomegalovirus infection in pregnancy. I. Laboratory evidence of congenital infection following maternal primary and reactivated infection. J. Infect., 1981, 3(1), 24-31.
13. Stagno, S.; Pass, R.F.; Dworsky, M.E.; Henderson, R.E.; Moore, E.G.; Walton, P.D.; Alford, C.A. Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infection. N. Engl. J. Med., 1982, 306(16), 945-949.
14. Stagno, S.; Pass, R.F.; Cloud, G.; Britt, W.J.; Henderson, R.E.; Walton, P.D.; Veren, D.A.; Page, F.; Alford, C.A. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA, 1986, 256(14), 1904-1908.
15. Griffiths, P.D.; Baboonian, C. A prospective study of primary cytomegalovirus infection during pregnancy: final report. Br. J. Obstet. Gynaecol., 1984, 91(4), 307-315.
16. Peckham, C.S.; Chin, K.S.; Coleman, J.C.; Henderson, K.; Hurley, R.; Preece, P.M. Cytomegalovirus infection in pregnancy: preliminary findings from a prospective study. Lancet, 1983, 1(8338), 1352-1355.
17. Ahlfors, K.; Ivarsson, S.A.; Harris, S.; Svanberg, L.; Holmqvist, R.; Lernmark, B.; Theander, G. Congenital cytomegalovirus infection and disease in Sweden and the relative importance of primary and secondary maternal infections. Preliminary findings from a prospective study. Scand. J. Infect. Dis., 1984, 16(2), 129-137.
18. Ahlfors, K.; Ivarsson, S.A.; Harris, S. Report on long-term study of maternal and congenital cytomegalovirus infection in Sweden. Review of prospective studies available in the literature. Scand. J. Infect. Dis., 1999, 31(5), 443-457.
19. Fowler, K.B.; Stagno, S.; Pass, R.F. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA, 2003, 289(8), 1008-1011.
20. Boppana, S.B.; Rivera, L.B.; Fowler, K.B.; Mach, M.; Britt, W.J. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N. Engl. J. Med., 2001, 344(18), 1366-1371.
21. Porath, A.; McNutt, R.A.; Smiley, L.M.; Weigle, K.A. Effectiveness and cost benefit of a proposed live cytomegalovirus vaccine in the prevention of congenital disease. Rev. Infect. Dis., 1990, 12(1), 31-40.
22. Arvin, A.M.; Fast, P.; Myers, M.; Plotkin, S.; Rabinovich, R.; National Vaccine Advisory Committee. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin. Infect. Dis., 2004, 39(2), 233-239.
23. Hibberd, P.L.; Snydman, D.R. Cytomegalovirus infection in organ transplant recipients. Infect. Dis. Clin. N. Am., 1995, 9(4), 863-877.
24. van der Bij, W.; Speich, R. Management of cytomegalovirus infection and disease after solid-organ transplantation. Clin. Infect. Dis., 2001, 33(Suppl. 1), S32-S37.
25. Hebart, H.; Kanz, L.; Jahn, G.; Einsele, H. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects. Drugs, 1998, 55(1), 59-72.
26. Paya, C.V. Indirect effects of CMV in the solid organ transplant patient. Transpl. Infect. Dis., 1999, 1(Suppl. 1), 8-12.
27. Pereyra, F.; Rubin, R.H. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr. Opin. Infect. Dis., 2004, 17(4), 357-361.
28. Jacobson, M.A. Current management of cytomegalovirus disease in patients with AIDS. AIDS Res. Hum. Retroviruses, 1994, 10(8), 917-923.
29. Drew, W.L. Cytomegalovirus infection in patients with AIDS. Clin. Infect. Dis., 1992, 14(2), 608-615.
30. Whitley, R.J.; Jacobson, M.A.; Friedberg, D.N.; Holland, G.N.; Jabs, D.A.; Dieterich, D.T.; Hardy, W.D.; Polis, M.A.; Deutsch, T.A.; Feinberg, J.; Spector, S.A.; Walmsley, S.; Drew, W.L.; Powderly, W.G.; Griffiths, P.D.; Benson, C.A.; Kessler, H.A. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. Arch. Intern. Med., 1998, 158(9), 957-969.
31. Steininger, C.; Puchhammer-Stöckl, E.; Popow-Kraupp, T. Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART). J. Clin. Virol., 2006, 37(1), 1-9.
32. Limaye, A.P.; Corey, L.; Koelle, D.M.; Davis, C.L.; Boeckh, M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet, 2000, 356(9230), 645-649.
33. Scott, G.M.; Weinberg, A.; Rawlinson, W.D.; Chou, S. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob. Agents Chemother., 2007, 51(1), 89-94.
34. French, M.A.; Price, P.; Stone, S.F. Immune restoration disease after antiretroviral therapy. AIDS, 2004, 18(12), 1615-1627.
35. Adler, S.P.; Starr, S.E.; Plotkin, S.A.; Hempfling, S.H.; Buis, J.; Manning, M.L.; Best, A.M. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J. Infect. Dis., 1995, 171(1), 26-32.
36. Farrell, H.E.; Shellam, G.R. Protection against murine cytomegalovirus infection by passive transfer of neutralizing and non- neutralizing monoclonal antibodies. J. Gen. Virol., 1991, 72(pt. 1), 149-156.
37. Shanley, J.D.; Jordan, M.C.; Stevens, J.G. Modification by adoptive humoral immunity of murine cytomegalovirus infection. J. Infect. Dis., 1981, 143(2), 231-237.
38. Enders, A.C. A comparative study of the fine structure of the trophoblast in several hemochorial placentas. Am. J. Anat., 1965, 116, 29-67.
39. Bratcher, D.F.; Bourne, N.; Bravo, F.J.; Schleiss, M.R.; Slaoui, M.; Myers, M.G.; Bernstein, D.I. Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. J. Infect. Dis., 1995, 172(4), 944-950.
40. Chatterjee, A.; Harrison, C.J.; Britt, W.J.; Bewtra, C. Modification of maternal and congenital cytomegalovirus infection by antiglycoprotein b antibody transfer in guinea pigs. J. Infect. Dis., 2001, 183(11), 1547-1553.
41. Yeager, A.S.; Grumet, F.C.; Hafleigh, E.B.; Arvin, A.M.; Bradley, J.S.; Prober, C.G. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J. Pediatr., 1981, 98(2), 281-287.
42. Adler, S.P.; Chandrika, T.; Lawrence, L.; Baggett, J. Cytomegalovirus infections in neonates acquired by blood transfusions. Pediatr. Infect. Dis., 1983, 2(2), 114-118.
43. Nigro, G.; Adler, S.P.; La Torre, R.; Best, A.M.; Congenital Cytomegalovirus Collaborating Group. Passive immunization during pregnancy for congenital cytomegalovirus infection. N. Engl. J. Med., 2005, 353(13), 1350-1362.
44. Snydman, D.R. Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease. Rev. Infect. Dis., 1990, 12(Suppl. 7), S839-S848.
45. King, S.M. Immune globulin versus antivirals versus combination for prevention of cytomegalovirus disease in transplant recipients. Antiviral Res., 1999, 40(3), 115-137.
46. Britt, W.J.; Vugler, L.; Stephens, E.B. Induction of complementdependent and -independent neutralizing antibodies by recombinant- derived human cytomegalovirus gp55-116 (gB). J. Virol., 1988, 62(9), 3309-3318.
47. Urban, M.; Klein, M.; Britt, W.J.; Hassfurther, E.; Mach, M. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J. Gen. Virol., 1996, 77(pt. 7), 1537-1547.
48. Simpson, J.A.; Chow, J.C.; Baker, J.; Avdalovic, N.; Yuan, S.; Au, D.; Co, M.S.; Vasquez, M.; Britt, W.J.; Coelingh, K.L. Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites. J. Virol., 1993, 67(1), 489-496.
49. Mach, M.; Kropff, B.; Dal Monte, P.; Britt, W. Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73). J. Virol., 2000, 74(24), 11881-11892.
50. Shimamura, M.; Mach, M.; Britt, W.J. Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virusneutralizing antibody response. J. Virol., 2006, 80(9), 4591-4600.
51. Ross, S. A.; Arora, N.; Novak, Z.; Fowler, K. B.; Britt, W. J.; Boppana, S. B. Cytomegalovirus reinfections in healthy seroimmune women. J. Infect. Dis., 2010, 201, 386-9.
52. Burkhardt, C.; Himmelein, S.; Britt, W.; Winkler, T.; Mach, M. Glycoprotein N subtypes of human cytomegalovirus induce a strain-specific antibody response during natural infection. J. Gen. Virol., 2009, 90, 1951-61.
53. Chou, S. W.; Dennison, K. M. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization- related epitopes. J. Infect. Dis., 1991, 163, 1229-34.
54. Urban, M.; Britt, W.; Mach, M. The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific. J. Virol., 1992, 66, 1303-11.
55. Pignatelli, S.; Dal Monte, P.; Rossini, G.; Chou, S.; Gojobori, T.; Hanada, K.; Guo, J. J.; Rawlinson, W.; Britt, W.; Mach, M.; Landini, M. P. Human cytomegalovirus glycoprotein N (gpUL73-gN) genomic variants: identification of a novel subgroup, geographical distribution and evidence of positive selective pressure. J. Gen. Virol., 2003, 84, 647-55.
56. Pignatelli, S.; Dal Monte, P.; Rossini, G.; Lazzarotto, T.; Gatto, M. R.; Landini, M. P. Intrauterine cytomegalovirus infection and glycoprotein N (gN) genotypes. J. Clin. Virol., 2003, 28, 38-43.
57. Greijer, A.E.; van de Crommert, J.M.; Stevens, S.J.; Middeldorp, J.M. Molecular fine-specificity analysis of antibody responses to human cytomegalovirus and design of novel synthetic-peptidebased serodiagnostic assays. J. Clin. Microbiol., 1999, 37(1), 179-188.
58. Scalzo, A.A.; Fitzgerald, N.A.; Wallace, C.R.; Gibbons, A.E.; Smart, Y.C.; Burton, R.C.; Shellam, G.R. The effect of the Cmv-1 resistance gene, which is linked to the natural killer cell gene complex, is mediated by natural killer cells. J. Immunol., 1992, 149(2), 581-589.
59. Brown, M.G.; Dokun, A.O.; Heusel, J.W.; Smith, H.R.; Beckman, D.L.; Blattenberger, E.A.; Dubbelde, C.E.; Stone, L.R.; Scalzo, A.A.; Yokoyama, W.M. Vital involvement of a natural killer cell activation receptor in resistance to viral infection. Science, 2001, 292(5518), 934-937.
60. Lee, S.H.; Girard, S.; Macina, D.; Busà, M.; Zafer, A.; Belouchi, A.; Gros, P.; Vidal, S.M. Susceptibility to mouse cytomegalovirus is associated with deletion of an activating natural killer cell receptor of the C-type lectin superfamily. Nat. Genet., 2001, 28(1), 42-45.
61. Daniels, K.A.; Devora, G.; Lai, W.C.; O'Donnell, C.L.; Bennett, M.; Welsh, R.M. Murine cytomegalovirus is regulated by a discrete subset of natural killer cells reactive with monoclonal antibody to Ly49H. J. Exp. Med., 2001, 194(1), 29-44.
62. Sylwester, A.W.; Mitchell, B.L.; Edgar, J.B.; Taormina, C.; Pelte, C.; Ruchti, F.; Sleath, P.R.; Grabstein, K.H.; Hosken, N.A.; Kern, F.; Nelson, J.A.; Picker, L.J. Broadly targeted human cytomegalovirus- specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med., 2005, 202(5), 673-685.
63. Wills, M.R.; Carmichael, A.J.; Mynard, K.; Jin, X.; Weekes, M.P.; Plachter, B.; Sissons, J.G. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J. Virol., 1996, 70(11), 7569-7579.
64. Boppana, S.B.; Britt, W.J. Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells. Virology, 1996, 222(1), 293-296.
65. Borysiewicz, L.K.; Hickling, J.K.; Graham, S.; Sinclair, J.; Cranage, M.P.; Smith, G.L.; Sissons, J.G. Human cytomegalovirusspecific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J. Exp. Med., 1988, 168(3), 919-931.
66. Lilleri, D.; Fornara, C.; Furione, M.; Zavattoni, M.; Revello, M.G.; Gerna, G. Development of human cytomegalovirus-specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus. J. Infect. Dis., 2007, 195(7), 1062-1070.
67. Gardner, M.B.; Officer, J.E.; Parker, J.; Estes, J.D.; Rongey, R.W. Induction of disseminated virulent cytomegalovirus infection by immunosuppression of naturally chronically infected wild mice. Infect. Immun., 1974, 10(4), 966-969.
68. Jordan, M.C.; Shanley, J.D.; Stevens, J.G. Immunosuppression reactivates and disseminates latent murine cytomegalovirus. J. Gen. Virol., 1977, 37(2), 419-423.
69. Reddehase, M.J.; Mutter, W.; Münch, K.; Bühring, H.J.; Koszinowski, U.H. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J. Virol., 1987, 61(10), 3102-3108.
70. Holtappels, R.; Podlech, J.; Grzimek, N.K.; Thomas, D.; Pahl- Seibert, M.F.; Reddehase, M.J. Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65). J. Virol., 2001, 75(14), 6584-6600.
71. Quinnan, G.V., Jr.; Kirmani, N.; Rook, A.H.; Manischewitz, J.F.; Jackson, L.; Moreschi, G.; Santos, G.W.; Saral, R.; Burns, W.H. Cytotoxic t cells in cytomegalovirus infection: HLA-restricted Tlymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrowtransplant recipients. N. Engl. J. Med., 1982, 307(1), 7-13.
72. Reusser, P.; Cathomas, G.; Attenhofer, R.; Tamm, M.; Thiel, G. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J. Infect. Dis., 1999, 180(2), 247-253.
73. Walter, E.A.; Greenberg, P.D.; Gilbert, M.J.; Finch, R.J.; Watanabe, K.S.; Thomas, E.D.; Riddell, S.R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med., 1995, 333(16), 1038-1044.
74. Lilleri, D.; Fornara, C.; Revello, M.G.; Gerna, G. Human cytomegalovirus- specific memory CD8+ and CD4+ T cell differentiation after primary infection. J. Infect. Dis., 2008, 198(4), 536-543.
75. Erlich, K.S.; Mills, J.; Shanley, J.D. Effects of L3T4+ lymphocyte depletion on acute murine cytomegalovirus infection. J. Gen. Virol., 1989, 70(pt. 7), 1765-1771.
76. Sester, M.; Sester, U.; Gärtner, B.; Heine, G.; Girndt, M.; Mueller- Lantzsch, N.; Meyerhans, A.; Köhler, H. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus- induced disease after renal transplantation. Transplantation, 2001, 71(9), 1287-1294.
77. Gamadia, L.E.; Remmerswaal, E.B.; Weel, J.F.; Bemelman, F.; van Lier, R.A.; Ten Berge, I.J. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood, 2003, 101(7), 2686-2692.
78. Herr, W.; Plachter, B. Cytomegalovirus and varicella-zoster virus vaccines in hematopoietic stem cell transplantation. Expert Rev. Vaccines, 2009, 8(8), 999-1021.
79. Marshall, G.S.; Plotkin, S.A. Progress toward developing a cytomegalovirus vaccine. Infect. Dis. Clin. N. Am., 1990, 4(2), 283-298.
80. Plotkin, S.A.; Farquhar, J.; Horberger, E. Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. J. Infect. Dis., 1976, 134(5), 470-475.
81. Plotkin, S.A.; Huang, E.S. Cytomegalovirus vaccine virus (Towne strain) does not induce latency. J. Infect. Dis., 1985, 152(2), 395-397.
82. Starr, S.E.; Glazer, J.P.; Friedman, H.M.; Farquhar, J.D.; Plotkin, S.A. Specific cellular and humoral immunity after immunization with live Towne strain cytomegalovirus vaccine. J. Infect. Dis., 1981, 143(4), 585-589.
83. Gönczöl, E.; Ianacone, J.; Furlini, G.; Ho, W.; Plotkin, S.A. Humoral immune response to cytomegalovirus Towne vaccine strain and to Toledo low-passage strain. J. Infect. Dis., 1989, 159(5), 851-859.
84. Jacobson, M.A.; Sinclair, E.; Bredt, B.; Agrillo, L.; Black, D.; Epling, C.L.; Carvidi, A.; Ho, T.; Bains, R.; Girling, V.; Adler, S.P. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. Vaccine, 2006, 24(25), 5311-5319.
85. Jacobson, M.A.; Sinclair, E.; Bredt, B.; Agrillo, L.; Black, D.; Epling, C.L.; Carvidi, A.; Ho, T.; Bains, R.; Adler, S.P. Antigenspecific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients. J. Clin. Virol., 2006, 35(3), 332-337.
86. Plotkin, S.A.; Smiley, M.L.; Friedman, H.M.; Starr, S.E.; Fleisher, G.R.; Wlodaver, C.; Dafoe, D.C.; Friedman, A.D.; Grossman, R.A.; Barker, C.F. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet, 1984, 1(8376), 528-530.
87. Balfour, H.H., Jr. Prevention of cytomegalovirus disease in renal allograft recipients. Scand. J. Infect. Dis. Suppl., 1991, 80, 88-93.
88. Plotkin, S.A.; Higgins, R.; Kurtz, J.B.; Morris, P.J.; Campbell, D.A., Jr.; Shope, T.C.; Spector, S.A.; Dankner, W.M. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation, 1994, 58(11), 1176-1178.
89. Plotkin, S.A. Vaccination against cytomegalovirus, the changeling demon. Pediatr. Infect. Dis. J., 1999, 18(4), 313-325.
90. Plotkin, S.A.; Starr, S.E.; Friedman, H.M.; Gönczöl, E.; Weibel, R.E. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J. Infect. Dis., 1989, 159(5), 860-865.
91. Quinnan, G.V., Jr.; Delery, M.; Rook, A.H.; Frederick, W.R.; Epstein, J.S.; Manischewitz, J.F.; Jackson, L.; Ramsey, K.M.; Mittal, K.; Plotkin, S.A.; Hilleman M.R. Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus. Ann. Intern. Med., 1984, 101(4), 478-483.
92. Adler, S.P.; Hempfling, S.H.; Starr, S.E.; Plotkin, S.A.; Riddell, S. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr. Infect. Dis. J., 1998, 17(3), 200-206.
93. Gill, T.A.; Morley, P.J.; Sweet, C. Replication-defective mutants of mouse cytomegalovirus protect against wild-type virus challenge. J. Med. Virol., 2000, 62(2), 127-139.
94. Cavanaugh, V.J.; Stenberg, R.M.; Staley, T.L.; Virgin, H.W. 4th; MacDonald, M.R.; Paetzold, S.; Farrell, H.E.; Rawlinson, W.D.; Campbell, A.E. Murine cytomegalovirus with a deletion of genes spanning HindIII-J and -I displays altered cell and tissue tropism. J. Virol., 1996, 70(3), 1365-1374.
95. MacDonald, M.R.; Li, X.Y.; Stenberg, R.M.; Campbell, A.E.; Virgin, H.W. 4th. Mucosal and parenteral vaccination against acute and latent murine cytomegalovirus (MCMV) infection by using an attenuated MCMV mutant. J. Virol., 1998, 72(1), 442-451.
96. Cicin-Sain, L.; Bubić, I.; Schnee, M.; Ruzsics, Z.; Mohr, C.; Jonjićs, S.; Koszinowski, U.H. Targeted deletion of regions rich in immune- evasive genes from the cytomegalovirus genome as a novel vaccine strategy. J. Virol., 2007, 81(24), 13825-13834.
97. Crumpler, M.M.; Choi, K.Y.; McVoy, M.A.; Schleiss, M.R. A live guinea pig cytomegalovirus vaccine deleted of three putative immune evasion genes is highly attenuated but remains immunogenic in a vaccine/challenge model of congenital cytomegalovirus infection. Vaccine, 2009, 27(31), 4209-4218.
98. Cha, T.A.; Tom, E.; Kemble, G.W.; Duke, G.M.; Mocarski, E.S.; Spaete, R.R. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J. Virol., 1996, 70(1), 78-83.
99. Mocarski, E.S., Jr.; Kemble, G.W. Recombinant cytomegaloviruses for study of replication and pathogenesis. Intervirology, 1996, 39(5-6), 320-330.
100. Heineman, T.C.; Schleiss, M.; Bernstein, D.I.; Spaete, R.R.; Yan, L.; Duke, G.; Prichard, M.; Wang, Z.; Yan, Q.; Sharp, M.A.; Klein, N.; Arvin, A.M.; Kemble, G. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J. Infect. Dis., 2006, 193(10), 1350-1360.
101. Britt, W.J.; Vugler, L.; Butfiloski, E.J.; Stephens, E.B. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J. Virol., 1990, 64(3), 1079-1085.
102. Ohlin, M.; Sundqvist, V.A.; Mach, M.; Wahren, B.; Borrebaeck, C.A. Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J. Virol., 1993, 67(2), 703-710.
103. Marshall, G.S.; Rabalais, G.P.; Stout, G.G.; Waldeyer, S.L. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J. Infect. Dis., 1992, 165(2), 381-384.
104. Gyulai, Z.; Endrész, V.; Burián, K.; Pincus, S.; Toldy, J.; Cox, W.I.; Meric, C.; Plotkin, S.; Gönczöl, E.; Berencsi, K. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1- Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J. Infect. Dis., 2000, 181(5), 1537-1546.
105. Harrison, C.J.; Britt, W.J.; Chapman, N.M.; Mullican, J.; Tracy, S. Reduced congenital cytomegalovirus (CMV) infection after maternal immunization with a guinea pig CMV glycoprotein before gestational primary CMV infection in the guinea pig model. J. Infect. Dis., 1995, 172(5), 1212-1220.
106. Bourne, N.; Schleiss, M.R.; Bravo, F.J.; Bernstein, D.I. Preconception immunization with a cytomegalovirus (CMV) glycoprotein vaccine improves pregnancy outcome in a guinea pig model of congenital CMV infection. J. Infect. Dis., 2001, 183(1), 59-64.
107. Schleiss, M.R.; Bourne, N.; Stroup, G.; Bravo, F.J.; Jensen, N.J.; Bernstein, D.I. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J. Infect. Dis., 2004, 189(8), 1374-1381.
108. Spaete, R.R. A recombinant subunit vaccine approach to HCMV vaccine development. Transplant. Proc., 1991, 23(3 Suppl. 3), 90-96.
109. Pass, R.F.; Duliège, A.M.; Boppana, S.; Sekulovich, R.; Percell, S.; Britt, W.; Burke, R.L. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J. Infect. Dis., 1999, 180(4), 970-975.
110. Frey, S.E.; Harrison, C.; Pass, R.F.; Yang, E.; Boken, D.; Sekulovich, R.E.; Percell, S.; Izu, A.E.; Hirabayashi, S.; Burke, R.L.; Duliège, A.M. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J. Infect. Dis., 1999, 180(5), 1700-1703.
111. Pass, R.F.; Zhang, C.; Evans, A.; Simpson, T.; Andrews, W.; Huang, M.L.; Corey, L.; Hill, J.; Davis, E.; Flanigan, C.; Cloud, G. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med., 2009, 360(12), 1191-1199.
112. Stanberry, L.R.; Rosenthal, S.L.; Mills, L.; Succop, P.A.; Biro, F.M.; Morrow, R.A.; Bernstein, D.I. Longitudinal risk of herpes simplex virus (HSV) type 1, HSV type 2, and cytomegalovirus infections among young adolescent girls. Clin. Infect. Dis., 2004, 39(10), 1433-1438.
113. Meyer-König, U.; Haberland, M.; von Laer, D.; Haller, O.; Hufert, F.T. Intragenic variability of human cytomegalovirus glycoprotein B in clinical strains. J. Infect. Dis., 1998, 177(5), 1162-1169.
114. Fries, B.C.; Chou, S.; Boeckh, M.; Torok-Storb, B. Frequency distribution of cytomegalovirus envelope glycoprotein genotypes in bone marrow transplant recipients. J. Infect. Dis., 1994, 169(4), 769-774.
115. Rasmussen, L.; Hong, C.; Zipeto, D.; Morris, S.; Sherman, D.; Chou, S.; Miner, R.; Drew, W.L.; Wolitz, R.; Dowling, A.; Warford, A.; Merigan, T.C. Cytomegalovirus gB genotype distribution differs in human immunodeficiency virus-infected patients and immunocompromised allograft recipients. J. Infect. Dis., 1997, 175(1), 179-184.
116. Rasmussen, L. Molecular pathogenesis of human cytomegalovirus infection. Transpl. Infect. Dis., 1999, 1(2), 127-134.
117. Bale, J.F., Jr.; Murph, J.R.; Demmler, G.J.; Dawson, J.; Miller, J.E.; Petheram, S.J. Intrauterine cytomegalovirus infection and glycoprotein B genotypes. J. Infect. Dis., 2000, 182(3), 933-936.
118. Shen, S.; Wang, S.; Britt, W.J.; Lu, S. DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates. Vaccine, 2007, 25(17), 3319-3327.
119. Schleiss, M.R.; Lacayo, J.C.; Belkaid, Y.; McGregor, A.; Stroup, G.; Rayner, J.; Alterson, K.; Chulay, J.D.; Smith, J.F. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J. Infect. Dis., 2007, 195(6), 789-798.
120. Paston, S.J.; Dodi, I.A.; Madrigal, J.A. Progress made towards the development of a CMV peptide vaccine. Hum. Immunol., 2004, 65(5), 544-549.
121. Diamond, D.J.; York, J.; Sun, J.Y.; Wright, C.L.; Forman, S.J. Development of a candidate HLA A 0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood, 1997, 90(5), 1751-1767.
122. La Rosa, C.; Krishnan, R.; Markel, S.; Schneck, J.P.; Houghten, R.; Pinilla, C.; Diamond, D.J. Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries. Blood, 2001, 97(6), 1776-1786.
123. Longmate, J.; York, J.; La Rosa, C.; Krishnan, R.; Zhang, M.; Senitzer, D.; Diamond, D.J. Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes. Immunogenetics, 2001, 52(3-4), 165-173.
124. Plotkin, S.A.; Cadoz, M.; Meignier, B.; Méric, C.; Leroy, O.; Excler, J.L.; Tartaglia, J.; Paoletti, E.; Gönczöl, E.; Chappuis, G. The safety and use of canarypox vectored vaccines. Dev. Biol. Stand., 1995, 84, 165-170.
125. Gönczöl, E.; Berensci, K.; Pincus, S.; Endrész, V.; Méric, C.; Paoletti, E.; Plotkin, S.A. Preclinical evaluation of an ALVAC (canarypox)-- human cytomegalovirus glycoprotein B vaccine candidate. Vaccine, 1995, 13(12), 1080-1085.
126. Adler, S.P.; Plotkin, S.A.; Gönczöl, E.; Cadoz, M.; Méric, C.; Wang, J.B.; Dellamonica, P.; Best, A.M.; Zahradnik, J.; Pincus, S.; Berencsi, K.; Cox, W.I.; Gyulai, Z. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J. Infect. Dis., 1999, 180(3), 843-846.
127. Berencsi, K.; Gyulai, Z.; Gönczöl, E.; Pincus, S.; Cox, W.I.; Michelson, S.; Kari, L.; Méric, C.; Cadoz, M.; Zahradnik, J.; Starr, S.; Plotkin, S. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J. Infect. Dis., 2001, 183(8), 1171-1179.
128. Berencsi, K.; Rando, R.F.; deTaisne, C.; Paoletti, E.; Plotkin, S.A.; Gönczöl, E. Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB. J. Gen. Virol., 1993, 74(pt. 11), 2507-2512.
129. Marshall, G.S.; Ricciardi, R.P.; Rando, R.F.; Puck, J.; Ge, R.W.; Plotkin, S.A.; Gönczöl, E. An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies. J. Infect. Dis., 1990, 162(5), 1177-1181.
130. Jonjić, S.; del Val, M.; Keil, G.M.; Reddehase, M.J.; Koszinowski, U.H. A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection. J. Virol., 1988, 62(5), 1653-1658.
131. Wang, Z.; La Rosa, C.; Maas, R.; Ly, H.; Brewer, J.; Mekhoubad, S.; Daftarian, P.; Longmate, J.; Britt, W.J.; Diamond, D.J. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J. Virol., 2004, 78(8), 3965-3976.
132. Shanley, J.D.; Wu, C.A. Intranasal immunization with a replication- deficient adenovirus vector expressing glycoprotein H of murine cytomegalovirus induces mucosal and systemic immunity. Vaccine, 2005, 23(8), 996-1003.
133. Rist, M.; Cooper, L.; Elkington, R.; Walker, S.; Fazou, C.; Tellam, J.; Crough, T.; Khanna, R. Ex vivo expansion of human cytomegalovirus- specific cytotoxic T cells by recombinant polyepitope: implications for HCMV immunotherapy. Eur. J. Immunol., 2005, 35(3), 996-1007.
134. Zhong, J.; Rist, M.; Cooper, L.; Smith, C.; Khanna, R. Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus. PLoS One, 2008, 3(9), e3256.
135. Del Val, M.; Schlicht, H.J.; Volkmer, H.; Messerle, M.; Reddehase, M.J.; Koszinowski, U.H. Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J. Virol., 1991, 65(7), 3641-3646.
136. Wang, Z.; La Rosa, C.; Lacey, S.F.; Maas, R.; Mekhoubad, S.; Britt, W.J.; Diamond, D.J. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. J. Clin. Virol., 2006, 35(3), 324-331.
137. Abel, K.; Strelow, L.; Yue, Y.; Eberhardt, M.K.; Schmidt, K.A.; Barry, P.A. A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus. Vaccine, 2008, 26(47), 6013-6025.
138. Rayner, J.O.; Dryga, S.A.; Kamrud, K.I. Alphavirus vectors and vaccination. Rev. Med. Virol., 2002, 12(5), 279-296.
139. Pushko, P.; Parker, M.; Ludwig, G.V.; Davis, N.L.; Johnston, R.E.; Smith, J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology, 1997, 239(2), 389-401.
140. Reap, E.A.; Dryga, S.A.; Morris, J.; Rivers, B.; Norberg, P.K.; Olmsted, R.A.; Chulay, J.D. Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins. Clin. Vaccine Immunol., 2007, 14(6), 748-755.
141. Bernstein, D.I.; Reap, E.A.; Katen, K.; Watson, A.; Smith, K.; Norberg, P.; Olmsted, R.A.; Hoeper, A.; Morris, J.; Negri, S.; Maughan, M.F.; Chulay, J.D. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine, 2009, 28(2), 484-493.
142. Donnelly, J.J.; Wahren, B.; Liu, M.A. DNA vaccines: progress and challenges. J. Immunol., 2005, 175(2), 633-639.
143. Pande, H.; Campo, K.; Tanamachi, B.; Forman, S.J.; Zaia, J.A. Direct DNA immunization of mice with plasmid DNA encoding the tegument protein pp65 (ppUL83) of human cytomegalovirus induces high levels of circulating antibody to the encoded protein. Scand. J. Infect. Dis. Suppl., 1995, 99, 117-120.
144. Endrész, V.; Kari, L.; Berencsi, K.; Kari, C.; Gyulai, Z.; Jeney, C.; Pincus, S.; Rodeck, U.; Méric, C.; Plotkin, S.A.; Gönczöl, E. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)- specific neutralizing antibody and phosphoprotein 65 (pp65)- specific cytotoxic T lymphocyte responses by naked DNA immunization. Vaccine, 1999, 17(1), 50-58.
145. Endrész, V.; Burián, K.; Berencsi, K.; Gyulai, Z.; Kari, L.; Horton, H.; Virok, D.; Méric, C.; Plotkin, S.A.; Gönczöl, E. Optimization of DNA immunization against human cytomegalovirus. Vaccine, 2001, 19(28-29), 3972-3980.
146. González Armas, J.C.; Morello, C.S.; Cranmer, L.D.; Spector, D.H. DNA immunization confers protection against murine cytomegalovirus infection. J. Virol., 1996, 70(11), 7921-7928.
147. Morello, C.S.; Cranmer, L.D.; Spector, D.H. Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65). J. Virol., 2000, 74(8), 3696-3708.
148. Morello, C.S.; Ye, M.; Spector, D.H. Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication. J. Virol., 2002, 76(10), 4822-4835.
149. Morello, C.S.; Ye, M.; Hung, S.; Kelley, L.A.; Spector, D.H. Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge. J. Virol., 2005, 79(1), 159-175.
150. Varnum, S.M.; Streblow, D.N.; Monroe, M.E.; Smith, P.; Auberry, K.J.; Pasa-Tolic, L.; Wang, D.; Camp, D.G., 2nd; Rodland, K.; Wiley, S.; Britt, W.; Shenk, T.; Smith, R.D.; Nelson, J.A. Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J. Virol., 2004, 78(20), 10960-10966.
151. Yue, Y.; Kaur, A.; Eberhardt, M.K.; Kassis, N.; Zhou, S.S.; Tarantal, A.F.; Barry, P.A. Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques. J. Virol., 2007, 81(3), 1095-1109.
152. Wloch, M.K.; Smith, L.R.; Boutsaboualoy, S.; Reyes, L.; Han, C.; Kehler, J.; Smith, H.D.; Selk, L.; Nakamura, R.; Brown, J.M.; Marbury, T.; Wald, A.; Rolland, A.; Kaslow, D.; Evans, T.; Boeckh, M. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J. Infect. Dis., 2008, 197(12), 1634-1642.
153. Pepperl, S.; Münster, J.; Mach, M.; Harris, J.R.; Plachter, B. Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J. Virol., 2000, 74(13), 6132-6146.
154. Pepperl-Klindworth, S.; Frankenberg, N.; Plachter, B. Development of novel vaccine strategies against human cytomegalovirus infection based on subviral particles. J. Clin. Virol., 2002, 25(Suppl. 2), S75-S85.
155. Tartaglia, J.; Excler, J.L.; El Habib, R.; Limbach, K.; Meignier, B.; Plotkin, S.; Klein, M. Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res. Hum. Retroviruses, 1998, 14(Suppl. 3), S291-S298.
156. Bernstein, D.I.; Schleiss, M.R.; Berencsi, K.; Gönczöl, E.; Dickey, M.; Khoury, P.; Cadoz, M.; Méric, C.; Zahradnik, J.; Duliège, A.M.; Plotkin, S. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J. Infect. Dis., 2002, 185(5), 686-690.
157. Jacobson, M.A.; Adler, S.P.; Sinclair, E.; Black, D.; Smith, A.; Chu, A.; Moss, R.B.; Wloch, M.K. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). Vaccine, 2009, 27(10), 1540-1548.